Desensitization of GABAergic receptors as a mechanism of zolpidem-induced somnambulism

Medical Hypotheses

Volumn 77, Issue 2, 2011, Pages 230-233

  Juszczak, Grzegorz R ^a  

^a INSTITUTE OF GENETICS AND ANIMAL BREEDING   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ESZOPICLONE; SEROTONIN; TRIAZOLAM; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ARTICLE; AUTOREGULATION; DRUG ABUSE; DRUG HALF LIFE; DRUG METABOLISM; HALLUCINATION; HUMAN; NONHUMAN; PARASOMNIA; RECEPTOR DOWN REGULATION; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL; SLEEP WALKING;

GABA-A RECEPTOR AGONISTS; HUMANS; HYPNOTICS AND SEDATIVES; MODELS, BIOLOGICAL; PYRIDINES; RECEPTORS, GABA-A; SEROTONERGIC NEURONS; SEROTONIN; SOMNAMBULISM;

EID: 79960647447     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.04.019     Document Type: Article

References (77)

1. Lam S.P., Fong S.Y., Yu M.W., Li S.X., Wing Y.K. Sleepwalking in psychiatric patients: comparison of childhood and adult onset. Aust N Z J Psychiatry 2009, 43:426-430.
2. Yang W., Dollear M., Muthukrishnan S.R. One rare side effect of zolpidem-sleepwalking: a case report. Arch Phys Med Rehabil 2005, 86:1265-1266.
3. Tsai J.H., Yang P., Chen C.C., et al. Zolpidem-induced amnesia and somnambulism: rare occurrences?. Eur Neuropsychopharmacol 2009, 19:74-76.
4. Dolder C.R., Nelson M.H. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs 2008, 22:1021-1036.
5. Siddiqui F., Osuna E., Chokroverty S. Writing emails as part of sleepwalking after increase in zolpidem. Sleep Med 2009, 10:262-264.
6. Hwang T.J., Ni H.C., Chen H.C., Lin Y.T., Liao S.C. Risk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study. J Clin Psychiatry 2010, 71:1331-1335.
7. Lam S.P., Fong S.Y., Ho C.K., Yu M.W., Wing Y.K. Parasomnia among psychiatric outpatients: a clinical, epidemiologic, cross-sectional study. J Clin Psychiatry 2008, 69:1374-1382.
8. Remulla A., Guilleminault C. Somnambulism (sleepwalking). Expert Opin Pharmacother 2004, 5:2069-2074.
9. Patsalos P.N. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 2005, 46(Suppl. 9):140-148.
10. Sancar F., Ericksen S.S., Kucken A.M., Teissere J.A., Czajkowski C. Structural determinants for high-affinity zolpidem binding to GABA-A receptors. Mol Pharmacol 2007, 71:38-46.
11. de Haas S.L., Schoemaker R.C., van Gerven J.M., Hoever P., Cohen A.F., Dingemanse J. Pharmacokinetics, pharmacodynamics and the pharmacokinetic/pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 2010, 24:1619-1629.
12. Riss J., Cloyd J., Gates J., Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008, 118:69-86.
13. Juszczak G.R., Swiergiel A.H. Serotonergic hypothesis of sleepwalking. Med Hypotheses 2005, 64:28-32.
14. Cape E.G., Jones B.E. Differential modulation of high-frequency gamma-electroencephalogram activity and sleep-wake state by noradrenaline and serotonin microinjections into the region of cholinergic basalis neurons. J Neurosci 1998, 18:2653-2666.
15. Kawashima T., Yamada S. Paroxetine-induced somnambulism. J Clin Psychiatry 2003, 64:483.
16. Khawaja I.S., Hurwitz T.D., Schenck C.H. Violent parasomnia associated with a selective serotonin reuptake inhibitor: a case report. J Clin Psychiatry 2008, 69:1982-1983.
17. Hafeez Z.H., Kalinowski C.M. Somnambulism induced by quetiapine: two case reports and a review of the literature. CNS Spectr 2007, 12:910-912.
18. Yeh Y.W., Chen C.H., Feng H.M., Wang S.C., Kuo S.C., Chen C.K. New onset somnambulism associated with different dosage of mirtazapine: a case report. Clin Neuropharmacol 2009, 32:232-233.
19. Chiu Y.H., Chen C.H., Shen W.W. Somnambulism secondary to olanzapine treatment in one patient with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:581-582.
20. Yang C., White D.P., Winkelman J.W. Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005, 58:510-514.
21. Winkelman J.W., James L. Serotonergic antidepressants are associated with REM sleep without atonia. Sleep 2004, 27:317-321.
22. Gervasoni D., Peyron C., Rampon C., et al. Role and origin of the GABAergic innervation of dorsal raphe serotonergic neurons. J Neurosci 2000, 20:4217-4225.
23. Karayannis T., Elfant D., Huerta-Ocampo I., et al. Slow GABA transient and receptor desensitization shape synaptic responses evoked by hippocampal neurogliaform cells. J Neurosci 2010, 30:9898-9909.
24. Mozrzymas J.W., Wojtowicz T., Piast M., Lebida K., Wyrembek P., Mercik K. GABA transient sets the susceptibility of mIPSCs to modulation by benzodiazepine receptor agonists in rat hippocampal neurons. J Physiol 2007, 585:29-46.
25. Lagrange A.H., Botzolakis E.J., Macdonald R.L. Enhanced macroscopic desensitization shapes the response of alpha4 subtype-containing GABAA receptors to synaptic and extrasynaptic GABA. J Physiol 2007, 578:655-676.
26. Mtchedlishvili Z., Kapur J. High-affinity, slowly desensitizing GABAA receptors mediate tonic inhibition in hippocampal dentate granule cells. Mol Pharmacol 2006, 69:564-575.
27. Ma P.M., Weiger W.A. Serotonin-containing neurons in lobsters: the actions of gamma-aminobutyric acid, octopamine, serotonin, and proctolin on activity of a pair of identified neurons in the first abdominal ganglion. J Neurophysiol 1993, 69:2015-2029.
28. Sohal V.S., Pangratz-Fuehrer S., Rudolph U., Huguenard J.R. Intrinsic and synaptic dynamics interact to generate emergent patterns of rhythmic bursting in thalamocortical neurons. J Neurosci 2006, 26:4247-4255.
29. Hallworth N.E., Bevan M.D. Globus pallidus neurons dynamically regulate the activity pattern of subthalamic nucleus neurons through the frequency-dependent activation of postsynaptic GABAA and GABAB receptors. J Neurosci 2005, 25:6304-6315.
30. Kiyatkin E.A., Rebec G.V. Heterogeneity of ventral tegmental area neurons: single-unit recording and iontophoresis in awake, unrestrained rats. Neuroscience 1998, 85:1285-1309.
31. Tadayonnejad R., Mehaffey W.H., Anderson D., Turner R.W. Reliability of triggering postinhibitory rebound bursts in deep cerebellar neurons. Channels (Austin) 2009, 3:149-155.
32. Carrascal L., Nieto-Gonzalez J.L., Cameron W.E., Torres B., Nunez-Abades P.A. Changes during the postnatal development in physiological and anatomical characteristics of rat motoneurons studied in vitro. Brain Res Brain Res Rev 2005, 49:377-387.
33. Sekirnjak C., Vissel B., Bollinger J., Faulstich M., du Lac S. Purkinje cell synapses target physiologically unique brainstem neurons. J Neurosci 2003, 23:6392-6398.
34. Burlhis T.M., Aghajanian G.K. Pacemaker potentials of serotonergic dorsal raphe neurons: contribution of a low-threshold Ca2+ conductance. Synapse 1987, 1:582-588.
35. Tadano T., Hozumi M., Satoh N., et al. Central serotonergic mechanisms on head twitch response induced by benzodiazepine receptor agonists. Pharmacology 2001, 62:157-162.
36. Tanaka M., Suemaru K., Watanabe S., Cui R., Li B., Araki H. Behavioral pharmacological properties after recovery from the loss of righting reflex induced by benzodiazepine receptor agonists in mice. Methods Find Exp Clin Pharmacol 2008, 30:607-613.
37. Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A., Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001, 29:1316-1324.
38. Shinomiya K., Shigemoto Y., Okuma C., Mio M., Kamei C. Effects of short-acting hypnotics on sleep latency in rats placed on grid suspended over water. Eur J Pharmacol 2003, 460:139-144.
39. Lau C.E., Sun L., Wang Q., Falk J.L. The effect of zolpidem on operant behavior and its relation to pharmacokinetics after intravenous and subcutaneous administration: concentration-effect relations. Behav Pharmacol 2002, 13:93-103.
40. Liskow B., Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior. J Am Acad Child Adolesc Psychiatry 2004, 43:927-928.
41. Moret C., Briley M. 5-HT autoreceptors in the regulation of 5-HT release from guinea pig raphe nucleus and hypothalamus. Neuropharmacology 1997, 36:1713-1723.
42. Adell A., Celada P., Artigas F. The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem 2001, 79:172-182.
43. Threlfell S., Greenfield S.A., Cragg S.J. 5-HT(1B) receptor regulation of serotonin (5-HT) release by endogenous 5-HT in the substantia nigra. Neuroscience 2010, 165:212-220.
44. Harsing L.G. The pharmacology of the neurochemical transmission in the midbrain raphe nuclei of the rat. Curr Neuropharmacol 2006, 4:313-339.
45. Oudiette D., Leu S., Pottier M., Buzare M.A., Brion A., Arnulf I. Dreamlike mentations during sleepwalking and sleep terrors in adults. Sleep 2009, 32:1621-1627.
46. Weinling E., McDougall S., Andre F., Bianchetti G., Dubruc C. Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol 2006, 20:397-403.
47. Greenblatt D.J., Legangneux E., Harmatz J.S., et al. Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 2006, 46:1469-1480.
48. Valiensi S.M., Cristiano E., Martinez O.A., Reisin R.C., Alvarez F. Sleep related eating disorders as a side effect of zolpidem. Medicina (B Aires) 2010, 70:223-226.
49. Najjar M. Zolpidem and amnestic sleep related eating disorder. J Clin Sleep Med 2007, 3:637-638.
50. Chiang A., Krystal A. Report of two cases where sleep related eating behavior occurred with the extended-release formulation but not the immediate-release formulation of a sedative-hypnotic agent. J Clin Sleep Med 2008, 4:155-156.
51. Liappas I.A., Malitas P.N., Dimopoulos N.P., et al. Three cases of zolpidem dependence treated with fluoxetine: the serotonin hypothesis. World J Biol Psychiatry 2003, 4:93-96.
52. Benyamina A., Dublanchet O., Karila L., Blecha L., Reynaud M. Intravenous zolpidem abuse: a case for serotonin depletion. Am J Addict 2007, 16:534.
53. Elko C.J., Burgess J.L., Robertson W.O. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. J Toxicol Clin Toxicol 1998, 36:195-203.
54. Coleman D.E., Ota K. Hallucinations with zolpidem and fluoxetine in an impaired driver. J Forensic Sci 2004, 49:392-393.
55. Terao T., Hikichi T. Serotonin syndrome in a case of depression with various somatic symptoms: the difficulty in differential diagnosis. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:295-296.
56. Sharma A., Dewan V.K. A case report of zolpidem-induced somnambulism. Prim Care Companion J Clin Psychiatry 2005, 7:74.
57. Sansone R.A., Sansone L.A. Zolpidem, somnambulism, and nocturnal eating. Gen Hosp Psychiatry 2008, 30:90-91.
58. Hoque R., Chesson A.L. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 2009, 5:471-476.
59. Wing Y.K., Lam S.P., Li S.X., Zhang J., Yu M.W. Sleep-related eating disorder and zolpidem: an open interventional cohort study. J Clin Psychiatry 2010, 71:653-656.
60. Drover D., Lemmens H., Naidu S., Cevallos W., Darwish M., Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 2000, 22:1443-1461.
61. Molina S.M., Joshi K.G. A case of zaleplon-induced amnestic sleep-related eating disorder. J Clin Psychiatry 2010, 71:210-211.
62. Dang A., Garg G., Rataboli P.V. Zolpidem induced nocturnal sleep-related eating disorder (NSRED) in a male patient. Int J Eat Disord 2009, 42:385-386.
63. Mendelson W.B. Sleepwalking associated with zolpidem. J Clin Psychopharmacol 1994, 14:150.
64. Yanes Baonza M., Ferrer Garcia-Borras J.M., Cabrera Majada A., Sanchez Gonzalez R. Sleep-walking linked to zolpidem. Aten Primaria 2003, 32:438.
65. Harazin J., Berigan T.R. Zolpidem tartrate and somnambulism. Mil Med 1999, 164:669-670.
66. Yun C.H., Ji K.H. Zolpidem-induced sleep-related eating disorder. J Neurol Sci 2010, 288:200-201.
67. Morgenthaler T.I., Silber M.H. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002, 3:323-327.
68. Fava G.A. Amnestic syndrome induced by zoplclone. Eur J Clin Pharmacol 1996, 50:509.
69. Greenblatt D.J., Gan L., Harmatz J.S., Shader R.I. Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. Br J Clin Pharmacol 2005, 60:244-248.
70. Sugimoto K., Araki N., Ohmori M., et al. Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol 2006, 62:209-215.
71. Schenck C.H., Hurwitz T.D., Bundlie S.R., Mahowald M.W. Sleep-related eating disorders: polysomnographic correlates of a heterogeneous syndrome distinct from daytime eating disorders. Sleep 1991, 14:419-431.
72. Menkes D.B. Triazolam-induced nocturnal bingeing with amnesia. Aust N Z J Psychiatry 1992, 26:320-321.
73. Lauerma H. Nocturnal wandering caused by restless legs and short-acting benzodiazepines. Acta Psychiatr Scand 1991, 83:492-493.
74. Ansseau M., Poncelet P.F., Schmitz D. High dose triazolam and anterograde amnesia. BMJ 1992, 304:1178.
75. Tornio A., Neuvonen P.J., Backman J.T. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol 2006, 62:645-651.
76. Ferentinos P., Paparrigopoulos T. Zopiclone and sleepwalking. Int J Neuropsychopharmacol 2009, 12:141-142.
77. Najib J. Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 2006, 28:491-516.